While many companies offer diagnostics based on synthetic genes and peptides diagnostic processes based on glycan arrays are not yet used for point-of-care applications. This proof-of principle project aimed to establish the business model for a company that will produce and commercialize glycosaminoglycan (GAG) arrays to diagnose the production of antibodies in response to anti-coagulant heparin treatment that results in heparin-induced thrombocytopenia (HIT). These arrays will serve as point-of-care diagnostics of HIT. The project was a success as not only did we establish specifications for a product as well as the cost structure for the production of the GAG array as well as the diagnostic devices. Based on an analysis of the IP space we developed an IP strategy, evaluated markets and established discussions with potential customers.
The company Berliner Diagnostik Werke GmbH was incorporated in Berlin, Germany in October 2016 and a first small round of financing has been concluded. The company is not yet employing any permanent staff but is currently in discussions with potential customers concerning a first deal.
